Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant CD274 (Atezolizumab Biosimilar) antibody

Reactivity: Human FACS, in vivo Host: Mouse Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN7200666
  • Target See all CD274 (Atezolizumab Biosimilar) products
    CD274 (Atezolizumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human
    Host
    • 1
    • 1
    Mouse
    Clonality
    • 2
    Monoclonal
    Conjugate
    • 2
    This CD274 (Atezolizumab Biosimilar) antibody is un-conjugated
    Application
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Purpose
    Atezolizumab Biosimilar, Human PD-L1 Monoclonal Antibody
    Specificity
    The in vivo grade atezolizumab biosimilar specifically binds to the human PDL1 protein.
    Characteristics
    Recombinant Humanized IgG1 Monoclonal Antibody.
    Purification
    Protein A affinity column
    Purity
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterility
    0.2 μm filtered
    Endotoxin Level
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody atezolizumab biosimilar was produced in the atezolizumab biosimilar CHO stable cell line.
    Isotype
    IgG1 kappa
  • Application Notes
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by atezolizumab.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Preservative
    Without preservative
    Handling Advice
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Expiry Date
    12 months
  • Target
    CD274 (Atezolizumab Biosimilar)
    Abstract
    CD274 (Atezolizumab Biosimilar) Products
    Synonyms
    B7-H antibody, B7H1 antibody, PD-L1 antibody, PDCD1L1 antibody, PDCD1LG1 antibody, PDL1 antibody, CD274 molecule antibody, CD274 antibody
    Target Type
    Biosimilar
    Background
    What is Atezolizumab biosimilar research grade? Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab.

    PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Atezolizumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
You are here: